Literature DB >> 30100686

Pharmaceutical Approval Update.

Mary Choy.   

Abstract

Lofexidine hydrocholoride (Lucemyra) for opioid withdrawal; erenumab-aooe (Aimovig) for migraine; and sodium zirconium cyclosilicate (Lokelma) for hyperkalemia.

Entities:  

Year:  2018        PMID： 30100686      PMCID： PMC6065498     

Source DB:  PubMed          Journal:  P T        ISSN： 1052-1372


  2 in total

1.  Development of chimeric and bifunctional antagonists for CLR/RAMP receptors.

Authors:  Chia Lin Chang; Sheau Yu Teddy Hsu
Journal:  PLoS One       Date:  2019-05-31       Impact factor: 3.240

Review 2.  A Comprehensive Update of Lofexidine for the Management of Opioid Withdrawal Symptoms.

Authors:  Ivan Urits; Anjana Patel; Robbie Zusman; Celina Guadalupe Virgen; Mohammad Mousa; Amnon A Berger; Hisham Kassem; Jai Won Jung; Jamal Hasoon; Alan D Kaye; Omar Viswanath
Journal:  Psychopharmacol Bull       Date:  2020-07-23
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.